Clinical Trial Update: Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

View source ↗

Summary

A real-world study evaluating trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer is currently recruiting (NCT06727227), s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: RECRUITING